A new framework published in Nature Medicine proposes a broader way of thinking about the value of cancer interventions by considering not only their demonstrated clinical benefit, but also whether health systems can realistically deliver that benefit to patients.
The Value Cube: translating clinical benefit into realizable value in global oncology
Authors: Bibek Aryal, Ophira Ginsburg and Dario Trapani
Nature Medicine, September 10, 2026, DOI: 10.1038/s41591-026-04634-w
The authors introduce the Value Cube, a three-dimensional framework intended to address a central challenge in global oncology: the value demonstrated by a cancer treatment in clinical research may not translate equally across healthcare systems with different resources, infrastructure, financing mechanisms, and delivery capacity.
Rather than presenting the framework as a finished assessment tool, the authors describe the publication as the beginning of a broader effort to develop a practical system for evaluating value across diverse healthcare settings.
From Clinical Benefit to Realizable Value
Modern oncology has developed increasingly sophisticated approaches for evaluating new treatments. However, Aryal, Ginsburg and Trapani argue that health-system capacity is often not formally incorporated into assessments of value.
This matters because clinical evidence can be applied internationally, while the conditions required to turn that evidence into meaningful patient benefit vary substantially between countries and health systems.
A therapy may demonstrate an important survival or quality-of-life benefit in a clinical trial, but realizing that benefit in practice may depend on the availability of appropriate diagnostics, trained healthcare professionals, treatment infrastructure, toxicity management, and sustainable financing.
The Value Cube therefore distinguishes between theoretical value and realizable value.
Theoretical value represents the potential value of an intervention based on what it can achieve. Realizable value reflects how much of that potential can actually be delivered within a particular healthcare environment.
This distinction places the health system itself within the assessment of value rather than treating implementation as a separate question that arises only after a therapy has already been judged valuable.
The Three Dimensions of the Value Cube
The framework considers value through three connected dimensions: context-relevant outcomes, delivery feasibility and true societal cost.
Context-relevant outcomes focus on what an intervention achieves for patients in the environment where it will actually be used. Delivery feasibility considers whether the healthcare system can provide that intervention safely, reliably and consistently. True societal cost expands the financial discussion beyond the price of a therapy alone by considering its consequences for patients, families and the wider health system.
The interaction of these dimensions determines how much of an intervention’s theoretical value can become realizable value.
The approach is particularly relevant to global oncology because the healthcare requirements surrounding many contemporary cancer treatments extend well beyond access to the medicine itself.
The authors illustrate this challenge through the 2025 WHO Model List of Essential Medicines, which added immune checkpoint inhibitors and biomarker-directed therapies for several high-burden cancers. They note that realizing the value of such treatments also depends on systems capable of identifying eligible patients, administering therapy safely, managing treatment-related toxicity, and financing care sustainably.
From this perspective, differences between healthcare systems can create not only an access gap, but also a gap between the potential value of a treatment and the value patients actually receive.
The Value Cube: Adapted conceptually from Aryal B, Ginsburg O, Trapani D. Nature Medicine (2026).
A Framework Designed to Evolve
The authors are clear that the Value Cube is currently a conceptual framework rather than a completed scoring instrument.
Writing about the publication on LinkedIn, Bibek Aryal described the paper as:
“A starting point, a conceptual foundation to build on, rather than a finished system.”
He explained that the next objective is to transform the Value Cube into an operational framework incorporating measurable indicators, scoring, and real-world testing. The team hopes to involve collaborators representing different regions and health-system settings by the end of 2026, with the next phase of the project expected to begin in early 2027.
That development process could be crucial to the framework’s eventual usefulness. A system designed for global oncology will need to remain meaningful across settings ranging from highly resourced cancer centers to health systems where access to pathology, molecular testing, medicines, specialists or supportive care may be limited.
The authors are therefore using the publication not only to introduce the Value Cube, but also to invite participation in its further development.
Aryal wrote:
“Please read the concept, challenge it, and improve it.”
He also invited members of the global oncology community interested in developing the next stage of the project to join the initiative.
Bridging Theoretical Benefit and Real-World Value
Commenting on the publication, Dario Trapani reflected on the development of the framework with Aryal and Ginsburg and emphasized the importance of connecting a treatment’s potential benefit with what healthcare systems can realistically provide.
Trapani wrote:
“Bridging the gap between a therapy’s theoretical benefit and its realizable value is so critical for global oncology.”
He also supported the call for wider participation, saying he was looking forward to hearing feedback from the oncology community and developing the next phase of the framework collaboratively.
That collaborative approach is central to the project. Instead of proposing a universal definition of value and applying it unchanged across countries, the Value Cube creates a structure for examining how clinical benefit interacts with the healthcare environment in which treatment is delivered.
Why the Value Cube could Matter for Global Oncology
The framework raises a fundamental question for cancer care: Can a treatment be considered equally valuable everywhere if the conditions required to deliver its benefits are not equally available?
For health systems, that question may have implications beyond decisions about individual medicines.
A therapy requiring sophisticated biomarker testing, for example, cannot provide its full potential benefit where eligible patients cannot reliably be identified. A treatment requiring intensive toxicity monitoring may have a different realizable value in a healthcare system without sufficient specialist or supportive-care capacity. Similarly, the financial consequences of treatment may extend beyond drug acquisition to the costs experienced by patients, families and healthcare services.
By bringing these factors together, the Value Cube could eventually provide a framework for examining cancer interventions in relation to the systems expected to deliver them.
However, substantial work remains before the concept can function as an operational value-assessment tool. The planned next phase will need to determine how its dimensions should be measured, how indicators should be scored and how the framework performs when tested across very different healthcare environments.
For Aryal, Ginsburg and Trapani, the publication is therefore less an endpoint than an invitation.
They aim to develop the Value Cube with input from the wider oncology community and explore whether a framework that evaluates both a cancer intervention and its delivery environment can provide a more realistic understanding of value in global cancer care.
Read further on OncoDaily: Discussions Around the DeLLphi-305 Trial
